B.Riley Financial Thinks Arrowhead Pharmaceuticals’ Stock is Going to Recover

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Arrowhead Pharmaceuticals (ARWRResearch Report) today and set a price target of $106.00. The company’s shares closed last Wednesday at $44.66, close to its 52-week low of $39.42.

According to, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.4% and a 23.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Spectrum Pharmaceuticals, and Allena Pharmaceuticals.

Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Moderate Buy with an average price target of $89.83.

See Insiders’ Hot Stocks on TipRanks >>

Arrowhead Pharmaceuticals’ market cap is currently $4.36B and has a P/E ratio of -23.56.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARWR in relation to earlier this year. Most recently, in January 2022, Christopher Richard Anzalone, the CEO of ARWR bought 11,806 shares for a total of $61,273.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Read More on ARWR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More